novo nordisk semaglutide clinical trials said on Tuesday its triple agonist UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to Novo Nordisk announces data from

In another randomized, double-blind study, three-month acetyl-l-carnitine supplementation provided statistically significant support for mental function, including memory and attention, compared to placebo

Jul 23, 2026Retatrutide reported two more successful Phase 3 trials 20.8% weight loss in people with type 2 diabetes and 22.6% in people with severe obesity and heart disease and Lilly pushed its FDA submission to early 2027

Persistent vomiting, nausea, or diarrhea that does not go away , particularly if you cannot maintain fluid intake

These symptoms may occur in the first few weeks or months of use but often fade after your body has adjusted to the medication

Physiological adaptations to weight loss and factors favouring weight regain

This is how language evolves now